EUVIMEDEUVIMED entdecken
Open Access

Patient‐reported disease burden in the Accelerate Clinical Trials in Charcot–Marie–Tooth Disease Study

T Rehbein iD, J Purks, N Dilek, S Behrens-Spraggins, J E Sowden, K J Eichinger iD, ACT‐CMT Study Group, J Burns, D Pareyson iD, S S Scherer iD, M M Reilly, M E Shy iD und 3 weitere

Journal of the Peripheral Nervous System · 2024-12 · 29 (4) · 487-493

DOI: 10.1111/jns.12662 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the Peripheral Nervous System, online erschienen am 10.10.2024. Verfasst von T Rehbein und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Rochester School of Medicine, Rochester, New York, USA. Hauptthemen laut MEDLINE: Charcot-Marie-Tooth Disease, Patient Reported Outcome Measures, Cost of Illness. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims The Charcot–Marie–Tooth Disease Health Index (CMT‐HI) is a disease‐specific, patient‐reported disease burden measure. As part of an international clinical trial readiness study, individuals with CMT1A (ages 18–75 years) underwent clinical outcome assessments (COAs), including the CMT‐HI, to capture their longitudinal perspective on the disease burden.

Methods

Two hundred and fifteen participants underwent serial COAs including the CMT‐HI, CMT Functional Outcome Measure (CMT‐FOM), CMT Neuropathy Score (CMTNSv2R), and CMT Exam Score (CMTES/CMTES‐R). Correlations between the total and subscale scores for the CMT‐HI and other COAs were determined. Changes in the CMT‐HI scores over 12 months were assessed using paired t ‐tests. The minimum clinically important difference (MCID) for the CMT‐HI and its subscales were calculated by anchoring to a participant global impression of change scale.

Results

At baseline, CMT1A participants were 44.5 ± 15 years old (range: 18–75) and 58% were women. The mean CMT‐HI was 25.7 ± 18.8 (range: 0–91.9; 100 reflecting maximal disease burden). The CMT‐HI correlated with the CMT‐FOM ( r = .54, p < .0001), CMTNSv2R ( r = .48, p < .0001), and CMTES/CMTES‐R ( r = .52/ r = .54, p < .0001). Disease burden was greater in women than in men (CMT‐HI 29.1 ± 19.1 vs. 21.2 ± 17.3, p = .001). Over 12 months, there was a nonsignificant mean increase in CMT‐HI of 0.40 ± 10.0 ( n = 189, p = .89). The MCID for the CMT‐HI total score was 3.8 points (95% CI: 1.7–5.9).

Discussion

Patient‐reported disease burden in CMT1A as measured by the CMT‐HI is associated with measures of neurologic impairment and physical functioning. Women reported a higher disease burden than men. These data will inform the design of clinical trials in CMT1A.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Charcot-Marie-Tooth DiseasePatient Reported Outcome MeasuresCost of IllnessHumansMiddle AgedMaleFemaleAdultAgedAdolescentYoung AdultSeverity of Illness Index

Stichwörter der Autor:innen

CMTCMT HICMT Health IndexCMT1ACharcot–Marie–tooth diseaseMCIDclinical trial designpatient‐reported outcomesquality of lifesex differences

Autor:innen und Institutionen

  • Department of Neurology, University of Rochester School of Medicine, Rochester, New York, USA.
  • Sydney School of Health Sciences, University of Sydney, Sydney, Australia.
  • Unit of Rare Neurological Diseases, Department of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
  • Department of Neurology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Centre for Neuromuscular Diseases, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College of London, London, UK.
  • Department of Neurology, University of Iowa, Carver School of Medicine, Iowa City, Iowa, USA.

ORCID-Profile: T Rehbein, K J Eichinger, D Pareyson, S S Scherer, M E Shy

Förderung

  • NINDS NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Rehbein, T., Purks, J., Dilek, N., Behrens-Spraggins, S., Sowden, J. E., Eichinger, K. J., ACT‐CMT Study Group, Burns, J., Pareyson, D., Scherer, S. S., Reilly, M. M., Shy, M. E., McDermott, M. P., Heatwole, C. R., & Herrmann, D. N. (2024). Patient‐reported disease burden in the Accelerate Clinical Trials in Charcot–Marie–Tooth Disease Study. Journal of the Peripheral Nervous System, 29(4), 487-493. https://doi.org/10.1111/jns.12662

Vancouver

Rehbein T, Purks J, Dilek N, Behrens-Spraggins S, Sowden JE, Eichinger KJ, et al. Patient‐reported disease burden in the Accelerate Clinical Trials in Charcot–Marie–Tooth Disease Study. Journal of the Peripheral Nervous System. 2024;29(4):487-493. doi:10.1111/jns.12662

BibTeX
@article{Rehbein2024,
  author = {Rehbein, T and Purks, J and Dilek, N and Behrens-Spraggins, S and Sowden, J E and Eichinger, K J and ACT‐CMT Study Group, ACT‐CMT Study Group and Burns, J and Pareyson, D and Scherer, S S and Reilly, M M and Shy, M E and McDermott, M P and Heatwole, C R and Herrmann, D N},
  title = {Patient‐reported disease burden in the Accelerate Clinical Trials in Charcot–Marie–Tooth Disease Study},
  journal = {Journal of the Peripheral Nervous System},
  year = {2024},
  volume = {29},
  number = {4},
  pages = {487--493},
  doi = {10.1111/jns.12662}
}
Kostenlos starten →